Skip to main content

What's Next in Precision Medicine? Small Molecule Biomarkers to Personalize Disease Prediction, Diagnostics and Therapies

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Mohit Jain, MD, Ph.D.

    Dr. Jain is a physician-scientist with nearly 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team of chemists, engineers, mathematicians, epidemiologists, and physicians to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across population-scale human studies. His work was supported by the NIH ONES Program grant and over $30M in federal, foundation, and industry funding. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating human discovery and drug development through the nexus of high throughput analytical mass spectrometry, computational biology, and population-scale clinical studies.

    Dr. Jain obtained his MD and Ph.D. from Boston University School of Medicine, and subsequently performed clinical residency and fellowship training in Internal Medicine, Cardiology, and Preventative Cardiology at Brigham and Women’s Hospital, Harvard Medical School. His postdoctoral work was performed at the Broad Institute and Massachusetts General Hospital in the HHMI laboratory, developing methods for large scale, mass spectrometry-based metabolomics and integrative computational analysis.

September 20, 2022
Tue 12:30 PM EDT

Duration 1H 30M

This live web event has ended.

For Technical Support
(888) 705-6002
+1 (858) 201-4136*
*for callers residing outside of the United States